For CAP requiring ICU admission without shock or MDR risk, what is a commonly used empiric regimen?

• A. Macrolide alone.
• B. Amoxicillin only.
• C. Doxycycline monotherapy.
• D. A beta-lactam plus a macrolide or a respiratory fluoroquinolone alone.

Answer: (D)

In ICU-capable pneumonia without shock or multidrug-resistant risk, the goal is to cover both typical bacteria (like Streptococcus pneumoniae and Haemophilus influenzae) and atypical pathogens (such as Mycoplasma, Chlamydophila, and Legionella) from the start. A beta-lactam antibiotic provides reliable coverage for the common typical organisms, while adding a macrolide (which has good activity against atypicals) ensures atypical pathogens are addressed. Alternatively, a respiratory fluoroquinolone alone can effectively cover both typical and atypical organisms in many cases.

So, regimens like a beta-lactam paired with a macrolide, or a single respiratory fluoroquinolone, are commonly used empirically in this setting. For example, ceftriaxone plus azithromycin is a classic two-drug approach, or levofloxacin/moxifloxacin can be used as monotherapy. The other options fall short because a macrolide alone misses typical bacteria, amoxicillin alone misses atypicals, and doxycycline alone may not provide reliable coverage or resistance considerations in ICU CAP.